18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of TreatmentPrimary· 12 weeks
Number of participants who achieved ≥ 75% reduction in PASI compared to baseline
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area s
Group
Value
95% CI
Secukinumab 2 mL PFS
64
Placebo
1
Participants With PASI 90 After 12 Weeks of TreatmentSecondary· 12 weeks
Number of participants who achieved ≥ 90% and 100% reduction in PASI compared to baseline
Group
Value
95% CI
Secukinumab 2 mL PFS
48
Placebo
1
Number of Participants With PASI 100 Response After 12 Weeks of TreatmentSecondary· 12 weeks
Participants who achieved 100% reduction in PASI compared to baseline
Group
Value
95% CI
Secukinumab 2 mL PFS
28
Secukinumab 2 x 1 mL PFS
26
Placebo
0
Number of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 ResponseSecondary· up to week 52
PASI response over time up to week 52: Number of participants who achieved ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
Week 1 IGA 0/1
Group
Value
95% CI
Secukinumab 2 mL PFS
1
Secukinumab 2 x 1 mL PFS
0
Placebo
0
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
0
Week 1 PASI 50
Group
Value
95% CI
Secukinumab 2 mL PFS
5
Secukinumab 2 x 1 mL PFS
5
Placebo
1
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
1
Week 1 PASI 75
Group
Value
95% CI
Secukinumab 2 mL PFS
0
Secukinumab 2 x 1 mL PFS
2
Placebo
0
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
0
Week 1 PASI 90
Group
Value
95% CI
Secukinumab 2 mL PFS
0
Secukinumab 2 x 1 mL PFS
0
Placebo
0
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
0
Week 1 PASI 100
Group
Value
95% CI
Secukinumab 2 mL PFS
0
Secukinumab 2 x 1 mL PFS
0
Placebo
0
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
0
Week 2 IGA 0/1
Group
Value
95% CI
Secukinumab 2 mL PFS
2
Secukinumab 2 x 1 mL PFS
1
Placebo
1
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
1
Week 2 PASI 50
Group
Value
95% CI
Secukinumab 2 mL PFS
18
Secukinumab 2 x 1 mL PFS
28
Placebo
1
Secukinumab 2 mL PFS Following Placebo
1
Secukinumab 2 x 1 mL PFS Following Placebo
0
Week 2 PASI 75
Group
Value
95% CI
Secukinumab 2 mL PFS
4
Secukinumab 2 x 1 mL PFS
5
Placebo
0
Secukinumab 2 mL PFS Following Placebo
0
Secukinumab 2 x 1 mL PFS Following Placebo
0
Participants With IGA Mod 2011 0 or 1 After 12 Weeks of TreatmentPrimary· 12 weeks
The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.
Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
Group
Value
95% CI
Secukinumab 2 mL PFS
55
Placebo
1
Adverse events — posted to ClinicalTrials.gov
Time frame: AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks.
Reporting threshold: 2%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria
· NA
· recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
· recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
· recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
· Phase 2
· recruiting
NCT07250997 — PALLAS Laser for Skin Diseases
· NA
· recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary
· Phase 3
· not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
· Phase 4
· not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
· not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
· not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+
· Phase 1, PHASE2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 15 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02748863.